GAIM fusions are therapeutic candidates for peripheral amyloidosis.

Autor: Proschitsky M; a Proclara Biosciences , Cambridge , MA , USA., Levenson J; a Proclara Biosciences , Cambridge , MA , USA., Lulu M; a Proclara Biosciences , Cambridge , MA , USA., Ward J; b Boston University Medical Center , Boston , MA , USA.; c Department of Radiology, Brigham and Womens Hospital , Boston , MA , USA., Shibad V; b Boston University Medical Center , Boston , MA , USA., Chung C; a Proclara Biosciences , Cambridge , MA , USA., Wall J; d Amyloidosis and Cancer Theranostics Program, University of Tennessee Medical Center , Knoxville , TN , USA., Kennel S; d Amyloidosis and Cancer Theranostics Program, University of Tennessee Medical Center , Knoxville , TN , USA., Fisher R; a Proclara Biosciences , Cambridge , MA , USA., Krishnan R; a Proclara Biosciences , Cambridge , MA , USA.
Jazyk: angličtina
Zdroj: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis [Amyloid] 2019; Vol. 26 (sup1), pp. 85-86.
DOI: 10.1080/13506129.2019.1590328
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje